Advertisement
Screener

CORCEPT THERAPEUTICS INC (CORT) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

CORCEPT THERAPEUTICS INC Financing Cash Flow

CORCEPT THERAPEUTICS INC (CORT) reported Financing Cash Flow of -$1.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-29

  • CORCEPT THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$2.04M.
  • CORCEPT THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $760.00K.
  • CORCEPT THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$31.22M.
  • CORCEPT THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$46.41M.
  • CORCEPT THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2025 was -$220.37M.
  • CORCEPT THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2024 was -$28.35M.
  • CORCEPT THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2023 was -$148.72M.
  • CORCEPT THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2022 was -$17.28M.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 158 monthNet Cash Provided by (Used in) Financing Activities 161 monthNet Cash Provided by (Used in) Financing Activities 164 monthNet Cash Provided by (Used in) Financing Activities 167 month
2026-06-30-$2.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
-$1.28M
10-Q · filed 2026-07-29
-$32.49M
derived: sum of 3 quarters · filed 2026-07-29
-$78.91M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$760.00K
10-Q · filed 2026-04-30
-$30.46M
derived: sum of 2 quarters · filed 2026-04-30
-$76.87M
derived: sum of 3 quarters · filed 2026-04-30
-$179.80M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31-$31.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$77.63M
derived: sum of 2 quarters · filed 2026-02-24
-$180.56M
derived: sum of 3 quarters · filed 2026-07-29
-$220.37M
10-K · filed 2026-02-24
2025-09-30-$46.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$149.35M
derived: sum of 2 quarters · filed 2026-07-29
-$189.15M
10-Q · filed 2025-11-04
-$193.71M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30-$102.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
-$142.74M
10-Q · filed 2026-07-29
-$147.30M
derived: sum of 3 quarters · filed 2026-07-29
-$168.39M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31-$39.80M
10-Q · filed 2026-04-30
-$44.37M
derived: sum of 2 quarters · filed 2026-04-30
-$65.46M
derived: sum of 3 quarters · filed 2026-04-30
-$67.61M
derived: sum of 4 quarters · filed 2026-04-30
2024-12-31-$4.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$25.66M
derived: sum of 2 quarters · filed 2026-02-24
-$27.81M
derived: sum of 3 quarters · filed 2026-02-24
-$28.35M
10-K · filed 2026-02-24
2024-09-30-$21.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$23.24M
derived: sum of 2 quarters · filed 2025-11-04
-$23.79M
10-Q · filed 2025-11-04
-$23.02M
derived: sum of 4 quarters · filed 2026-02-24
2024-06-30-$2.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31
-$2.69M
10-Q · filed 2025-07-31
-$1.93M
derived: sum of 3 quarters · filed 2026-02-24
-$5.84M
derived: sum of 4 quarters · filed 2026-02-24
2024-03-31-$543.00K
10-Q · filed 2025-05-05
$223.00K
derived: sum of 2 quarters · filed 2026-02-24
-$3.69M
derived: sum of 3 quarters · filed 2026-02-24
-$149.45M
derived: sum of 4 quarters · filed 2026-02-24
2023-12-31$766.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$3.15M
derived: sum of 2 quarters · filed 2026-02-24
-$148.90M
derived: sum of 3 quarters · filed 2026-02-24
-$148.72M
10-K · filed 2026-02-24
2023-09-30-$3.92M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
-$149.67M
derived: sum of 2 quarters · filed 2024-10-30
-$149.49M
10-Q · filed 2024-10-30
-$149.55M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30-$145.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-29
-$145.57M
10-Q · filed 2024-07-29
-$145.63M
derived: sum of 3 quarters · filed 2025-02-26
-$159.59M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$181.00K
10-Q · filed 2024-05-01
$120.00K
derived: sum of 2 quarters · filed 2025-02-26
-$13.84M
derived: sum of 3 quarters · filed 2025-02-26
-$16.60M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31-$61.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
-$14.02M
derived: sum of 2 quarters · filed 2025-02-26
-$16.78M
derived: sum of 3 quarters · filed 2025-02-26
-$17.28M
10-K · filed 2025-02-26
2022-09-30-$13.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01
-$16.72M
derived: sum of 2 quarters · filed 2023-11-01
-$17.22M
10-Q · filed 2023-11-01
-$224.19M
derived: sum of 4 quarters · filed 2024-02-15
2022-06-30-$2.76M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02
-$3.26M
10-Q · filed 2023-08-02
-$210.23M
derived: sum of 3 quarters · filed 2024-02-15
-$233.87M
derived: sum of 4 quarters · filed 2024-02-15
2022-03-31-$506.00K
10-Q · filed 2023-05-03
-$207.47M
derived: sum of 2 quarters · filed 2024-02-15
-$231.12M
derived: sum of 3 quarters · filed 2024-02-15
-$257.15M
derived: sum of 4 quarters · filed 2024-02-15
2021-12-31-$206.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15
-$230.61M
derived: sum of 2 quarters · filed 2024-02-15
-$256.64M
derived: sum of 3 quarters · filed 2024-02-15
-$302.59M
10-K · filed 2024-02-15
2021-09-30-$23.64M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
-$49.67M
derived: sum of 2 quarters · filed 2022-11-03
-$95.62M
10-Q · filed 2022-11-03
-$96.28M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30-$26.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$71.98M
10-Q · filed 2022-08-04
-$72.64M
derived: sum of 3 quarters · filed 2023-02-28
-$66.77M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31-$45.95M
10-Q · filed 2022-05-05
-$46.61M
derived: sum of 2 quarters · filed 2023-02-28
-$40.74M
derived: sum of 3 quarters · filed 2023-02-28
-$33.94M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31-$661.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$5.21M
derived: sum of 2 quarters · filed 2023-02-28
$12.01M
derived: sum of 3 quarters · filed 2023-02-28
$12.21M
10-K · filed 2023-02-28
2020-09-30$5.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$12.67M
derived: sum of 2 quarters · filed 2021-11-03
$12.88M
10-Q · filed 2021-11-03
$12.73M
derived: sum of 4 quarters · filed 2022-02-15
2020-06-30$6.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29
$7.01M
10-Q · filed 2021-07-29
$6.87M
derived: sum of 3 quarters · filed 2022-02-15
$9.56M
derived: sum of 4 quarters · filed 2022-02-15
2020-03-31$205.00K
10-Q · filed 2021-05-06
$61.00K
derived: sum of 2 quarters · filed 2022-02-15
$2.76M
derived: sum of 3 quarters · filed 2022-02-15
-$13.15M
derived: sum of 4 quarters · filed 2022-02-15
2019-12-31-$144.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15
$2.55M
derived: sum of 2 quarters · filed 2022-02-15
-$13.36M
derived: sum of 3 quarters · filed 2022-02-15
-$28.64M
10-K · filed 2022-02-15
2019-09-30$2.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03
-$13.21M
derived: sum of 2 quarters · filed 2020-11-03
-$28.50M
10-Q · filed 2020-11-03
-$40.53M
derived: sum of 4 quarters · filed 2021-02-23
2019-06-30-$15.91M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04
-$31.20M
10-Q · filed 2020-08-04
-$43.23M
derived: sum of 3 quarters · filed 2021-02-23
-$51.50M
derived: sum of 4 quarters · filed 2021-02-23
2019-03-31-$15.29M
10-Q · filed 2020-05-04
-$27.32M
derived: sum of 2 quarters · filed 2021-02-23
-$35.59M
derived: sum of 3 quarters · filed 2021-02-23
-$31.55M
derived: sum of 4 quarters · filed 2021-02-23
2018-12-31-$12.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23
-$20.30M
derived: sum of 2 quarters · filed 2021-02-23
-$16.26M
derived: sum of 3 quarters · filed 2021-02-23
-$14.34M
10-K · filed 2021-02-23
2018-09-30-$8.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
-$4.23M
derived: sum of 2 quarters · filed 2019-11-07
-$2.30M
10-Q · filed 2019-11-07
$263.00K
derived: sum of 4 quarters · filed 2020-02-24
2018-06-30$4.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
$5.97M
10-Q · filed 2019-08-01
$8.53M
derived: sum of 3 quarters · filed 2020-02-24
$6.69M
derived: sum of 4 quarters · filed 2020-02-24
2018-03-31$1.92M
10-Q · filed 2019-05-09
$4.49M
derived: sum of 2 quarters · filed 2020-02-24
$2.65M
derived: sum of 3 quarters · filed 2020-02-24
2017-12-31$2.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24
$726.00K
derived: sum of 2 quarters · filed 2020-02-24
-$7.95M
10-K · filed 2020-02-24
2017-09-30-$1.84M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02
-$10.52M
10-Q · filed 2018-11-02
2017-06-30-$8.68M
10-Q · filed 2018-08-09
2016-12-31-$7.10M
10-K · filed 2019-02-26
2013-12-31-$592.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
-$970.00K
10-K · filed 2014-03-14
2013-09-30-$378.00K
10-Q · filed 2013-11-12
2012-12-31$204.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
$76.21M
derived: sum of 2 quarters · filed 2014-03-14
$76.41M
derived: sum of 3 quarters · filed 2014-03-14
$89.57M
10-K · filed 2014-03-14
2012-09-30$76.01M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
$76.21M
derived: sum of 2 quarters · filed 2013-11-12
$89.36M
10-Q · filed 2013-11-12
$89.41M
derived: sum of 4 quarters · filed 2014-03-14
2012-06-30$198.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09
$13.35M
10-Q · filed 2013-08-09
$13.40M
derived: sum of 3 quarters · filed 2014-03-14
$13.68M
derived: sum of 4 quarters · filed 2014-03-14
2012-03-31$13.16M
10-Q · filed 2013-05-08
$13.20M
derived: sum of 2 quarters · filed 2014-03-14
$13.48M
derived: sum of 3 quarters · filed 2014-03-14
$13.72M
derived: sum of 4 quarters · filed 2014-03-14
$234.45M
10-Q · filed 2012-05-10
2011-12-31$45.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
$328.00K
derived: sum of 2 quarters · filed 2014-03-14
$564.00K
derived: sum of 3 quarters · filed 2014-03-14
$42.48M
10-K · filed 2014-03-14
$221.29M
10-K · filed 2012-03-13
2011-09-30$283.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08
$519.00K
derived: sum of 2 quarters · filed 2012-11-08
$42.44M
10-Q · filed 2012-11-08
$43.49M
derived: sum of 4 quarters · filed 2013-03-15
$221.25M
10-Q · filed 2011-11-08
2011-06-30$236.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
$42.15M
10-Q · filed 2012-08-09
$43.21M
derived: sum of 3 quarters · filed 2013-03-15
$43.23M
derived: sum of 4 quarters · filed 2013-03-15
$220.96M
10-Q · filed 2011-08-09
2011-03-31$41.92M
10-Q · filed 2012-05-10
$42.98M
derived: sum of 2 quarters · filed 2013-03-15
$42.99M
derived: sum of 3 quarters · filed 2013-03-15
2010-12-31$1.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15
$1.07M
derived: sum of 2 quarters · filed 2013-03-15
$23.00M
10-K · filed 2013-03-15
2010-09-30$17.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08
$21.94M
10-Q · filed 2011-11-08
2010-06-30$21.92M
10-Q · filed 2011-08-09
2009-12-31$23.52M
10-K · filed 2012-03-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52